NPC and Stella Pharma fell sharply in the Emerging Market Stock Digest. After trading ended on the 7th, NPC announced its results for the fiscal year ending August 2026 and provided its outlook for the fiscal year ending August 2027. Stella Pharma was reported to have a partial amendment to its application for approval of the indication for its BNCT drug “Steboronin” scheduled for review.
After trading ended on the 7th, NPC announced its results for the fiscal year ending August 2026. The company also presented a new earnings outlook.
According to the announcement, NPC reported revenue of ¥5.811 billion and ordinary profit of ¥880 million, representing year-on-year declines in both revenue and profit.
NPC also said that its initial forecast for the following year calls for revenue of ¥9.895 billion and ordinary profit of ¥1.417 billion for the fiscal year ending August 2027.
Meanwhile, Stella Pharma announced that its application for a partial amendment to the marketing approval of its BNCT drug “Steboronin,” adding recurrent meningioma as an indication, is scheduled for review by the Pharmaceutical Affairs and Food Sanitation Council. The preceding trial had shown significant efficacy measures, which form the basis for the review.
The market reaction was reportedly limited.